References
- Petrovich Z, Langholz B, Formenti S, Luxton G, Astrahan M. Management of carcinoma of the esophagus: the role of radiotherapy. Am J Clin Oncol 1991;14:80-86 https://doi.org/10.1097/00000421-199102000-00018
- Newaishy GA, Read GA, Duncan W, Kerr GR. Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. Clin Radiol 1982;33:347-352 https://doi.org/10.1016/S0009-9260(82)80288-2
- Schattenkerk ME, Obertop H, Mud HJ, Eijkenboom WM, van Andel JG, van Houten H. Survival after resection for carcinoma of the oesophagus. Br J Surg 1987;74: 165-168 https://doi.org/10.1002/bjs.1800740305
- Teniere p, Hay JM, Fingerhut A, Fagniez PL. Postoperative rad iation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 1991;173:123-130
- Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627 https://doi.org/10.1001/jama.281.17.1623
- Smith TJ, Ryan LM, Douglass HO, Jr., et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Bioi Phys 1998;42:269-276
- Wong RK, Malthaner RA, Zuraw L, Rumble RB. Combinedmodality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys 2003;55:930-942 https://doi.org/10.1016/S0360-3016(02)04278-5
- Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of com bined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-1174 https://doi.org/10.1200/JCO.20.5.1167
- Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467 https://doi.org/10.1056/NEJM199608153350702
- Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M. A phase I/II study of external beam radiation,brachytherapy, and concurrent chemotherapy for patients withlocalized carcinoma of the esophagus (Radiation Therapy OncologyGroup Study 9207): final report. Cancer 2000;88:988-995 https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5<988::AID-CNCR7>3.0.CO;2-U
- Hishikawa y, Kurisu K, Taniguchi M, Kamikonya N, Miura T. High-dose-rate intraluminal brachytherapy (HDRIBT)for esophageal cancer. Int J Radiat Oncol Biol Phys 1991;21:1133-1135 https://doi.org/10.1016/0360-3016(91)90267-8
- Sur RK, Singh DP, Sharma SC, et al. Radiation therapy of esophageal cancer: role of high dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1992;22:1043-1046 https://doi.org/10.1016/0360-3016(92)90805-R
- Chung WK, Ahn SJ, Nah BS. The radiotherapy result of esophageal cancer. J Korean Soc Ther Radiol Oncol 1991;9:241-248
- Ahn SJ, Chung WK, Nah BS, Nam TK. External beam radiotherapy alone in advanced esophageal cancer. J Korean Soc Ther Radiol Oncol 2000;18:11-16
- Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985;58:515-528 https://doi.org/10.1259/0007-1285-58-690-515
- American Joint Committee on Cancer. Manual for staging of cancer. 5th ed. Philadelphia, PA: Lippincott, 1997:57-611
- Hill MC, Ahlgren JD, Gomes MN, Roberts 1M. Esophageal cancer: detection and staging. In: Ahlgren JD, Macdonald JS, eds. Gastrointestinal Oncology. Philadelphia, PA: Lippincott Co. 1992:81-88
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346 https://doi.org/10.1016/0360-3016(95)00060-C
- Chan A, Wong A, Arthur K. Concomitant 5-fluorouracil infusion, mitomycin C and radical radiation therapy in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1989;16:59-65 https://doi.org/10.1016/0360-3016(89)90010-2
- Seitz JF, Giovannini M, Padaut-Cesana J, et al. Inoperable nonmetastatic squamous cell carcinoma of the esophagus managed by concomitant chemotherapy (5-fluorouracil and cisplatin) and radiation therapy. Cancer 1990;66:214-219 https://doi.org/10.1002/1097-0142(19900715)66:2<214::AID-CNCR2820660204>3.0.CO;2-Z
- Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E, Olweny C. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol 1992;10:1037-1043 https://doi.org/10.1200/JCO.1992.10.7.1037
- Gaspar LE, Nag S, Herskovic A, Mantravadi R, Speiser B. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. Int J Radiat Oncol Biol Phys 1997;38:127-132 https://doi.org/10.1016/S0360-3016(97)00231-9
- Lee CG, Suh CO, Kim GE, Chu SS, Chung EJ, Kim WC. The role of intraluminal brachytherapy in management of esophageal cancer. J Korean Soc Ther Radiol Oncol 1995;13:331-338
- Richmond J, Seydel HG, Bae Y, Lewis J, Burdakin J, Jacobsen G. Comparison of three treatment strategies for esophageal cancer within a single institution. Int J Radiat Oncol Biol Phys 1987;13:1617-1620 https://doi.org/10.1016/0360-3016(87)90155-6
- Safran H, Gaissert H, Akerman p, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19:1-7 https://doi.org/10.1081/CNV-100000068
- Iison DH, Bains M, Kelsen DP, et al.Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 2003;21:2926-2932 https://doi.org/10.1200/JCO.2003.02.147
- Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann EH, Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002;21:657-663 https://doi.org/10.1016/S1010-7940(02)00044-1
- Akamatsu M, Matsumoto T, aka K, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003;57:1323-1327 https://doi.org/10.1016/S0360-3016(03)00782-X
- Giovannini M, Seitz JF, Thomas p, et al. Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer. Endoscopy 1997;29:4-9 https://doi.org/10.1055/s-2007-1004053
- Lim JT, Truong PT, Berthelet E, et al. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radia Oncol Biol Phys 2003;57:1328-1335 https://doi.org/10.1016/S0360-3016(03)00751-X
- Zuccaro G, Jr., Rice TW, Goldblum J, et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am Gastroenterol 1999;94:906-912 https://doi.org/10.1111/j.1572-0241.1999.985_h.x